May Marie Cheline

Ms. May Marie Cheline

Chemistry and Biochemistry, Kent State University, Kent, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ASArpit Sharma
Arpit Sharma
WJWjdan Jogadi
Wjdan Jogadi
MKMan Kshetri
Man Kshetri
SASuha Alqarni
Suha Alqarni
AAAl Amin
Al Amin
YZyaorong zheng
yaorong zheng

12 July 2023 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
AJAmarasooriya M. D. S. Jayawardhana
Amarasooriya M. D. S. Jayawardhana
SBSrijana Bhandari
Srijana Bhandari
AKAriela W. Kaspi-Kaneti
Ariela W. Kaspi-Kaneti
MKMan Kshetri
Man Kshetri
ZQZihan Qiu
Zihan Qiu
YZyaorong zheng
yaorong zheng
Visible light-activatable Pt( iv ) prodrugs harness the upregulated CD36 to facilitate cell entry and killing of drug resistant ovarian cancer cells.

29 August 2024 in Molecules
Verified
Journal Article
Open access
PDF file
WJWjdan Jogadi
Wjdan Jogadi
MKMan Kshetri
Man Kshetri
SASuha Alqarni
Suha Alqarni
ASArpit Sharma
Arpit Sharma
May Marie ChelineMay Marie Cheline
May Marie Cheline
YZyaorong zheng
yaorong zheng
In this study, we report a novel platinum–doxorubicin conjugate that demonstrates superior therapeutic indices to cisplatin, doxorubicin, or their combination, which are commonly used in cancer treatment. This new molecular structure (1) was formed by conjugating an amphiphilic Pt(IV) prodrug of cisplatin with doxorubicin. Due to its amphiphilic nature, the Pt(IV)–doxorubicin conjugate effectively penetrates cell membranes, delivering both cisplatin and doxorubicin payloads intracellularly. The intracellular accumulation of these payloads was assessed using graphite furnace atomic absorption spectrometry and fluorescence imaging. Since the therapeutic effects of cisplatin and doxorubicin stem from their ability to target nuclear DNA, we hypothesized that the amphiphilic Pt(IV)–doxorubicin conjugate (1) would effectively induce nuclear DNA damage toward killing cancer cells. To test this hypothesis, we used flow the cytometric analysis of phosphorylated H2AX (γH2AX), a biomarker of nuclear DNA damage. The Pt(IV)–doxorubicin conjugate (1) markedly induced γH2AX in treated MDA-MB-231 breast cancer cells, showing higher levels than cells treated with either cisplatin or doxorubicin alone. Furthermore, MTT cell viability assays revealed that the enhanced DNA-damaging capability of complex 1 resulted in superior cytotoxicity and selectivity against human cancer cells compared to cisplatin, doxorubicin, or their combination. Overall, the development of this amphiphilic Pt(IV)–doxorubicin conjugate represents a new form of combination therapy with improved therapeutic efficacy.

Verified
Journal Article
Open access
PDF file
MKMan Kshetri
Man Kshetri
WJWjdan Jogadi
Wjdan Jogadi
SASuha Alqarni
Suha Alqarni
PDPayel Datta
Payel Datta
May Marie ChelineMay Marie Cheline
May Marie Cheline
YZyaorong zheng
yaorong zheng
We conducted the first comprehensive investigation on the impact of head group modifications on the anticancer activities of fatty-acid-like Pt(IV) prodrugs (FALPs), which are a class of platinum-based metallodrugs that target mitochondria. We created a small library of FALPs (1–9) with diverse head group modifications. The outcomes of our study demonstrate that hydrophilic modifications exclusively enhance the potency of these metallodrugs, whereas hydrophobic modifications significantly decrease their cytotoxicity. To further understand this interesting structure–activity relationship, we chose two representative FALPs (compounds 2 and 7) as model compounds: one (2) with a hydrophilic polyethylene glycol (PEG) head group, and the other (7) with a hydrophobic hydrocarbon modification of the same molecular weight. Using these FALPs, we conducted a targeted investigation on the mechanism of action. Our study revealed that compound 2, with hydrophilic modifications, exhibited remarkable penetration into cancer cells and mitochondria, leading to subsequent mitochondrial and DNA damage, and effectively eradicating cancer cells. In contrast, compound 7, with hydrophobic modifications, displayed a significantly lower uptake and weaker cellular responses. The collective results present a different perspective, indicating that increased hydrophobicity may not necessarily enhance cellular uptake as is conventionally believed. These findings provide valuable new insights into the fundamental principles of developing metallodrugs.